Here’s a breakdown of the provided text, focusing on key information and summarizing the study’s findings:
Main Topic: optimizing Venetoclax Dosage in Acute Myeloid Leukemia (AML) Treatment
Key Problem: While the combination of venetoclax and hypomethylating agents (HMA) is a meaningful advancement for older/unfit AML patients, the standard 400mg 28-day venetoclax regimen frequently enough leads to significant hematological toxicities (low blood cell counts), causing treatment interruptions and possibly reducing survival.
Study Overview:
* Researchers: Okta S, Ueda-Akagi Y, Mitsuyoshi T, Ono K.
* Published: Leukemia & Lymphoma (December 25,2025)
* Design: Prospective study evaluating different venetoclax dosing strategies in 4431 newly diagnosed AML patients receiving venetoclax + 5-azacitidine.
* Groups:
* Group A (Standard): 400mg venetoclax for 28 days (n=12)
* Group B (shortened): 400mg venetoclax for 14 days (n=15)
* Group C (Reduced Dose): 100mg venetoclax for 21 days (n=18)
Key Findings:
* Higher Remission Rates: Modified regimens (Groups B & C) showed higher complete remission (CR) and composite remission (CRc) rates compared to the standard dose (Group A). (67% vs 58% CR, 73%/72% vs 58% CRc)
* Faster Remission: Time to CRc was shorter in Groups B and C.
* Improved Survival: Overall survival was substantially longer in patients receiving the modified regimens (HR 0.46, P = 0.033).
* Reduced Toxicity: Modified regimens resulted in:
* Lower rates of febrile neutropenia (a risky infection risk due to low white blood cells).
* Shorter duration of febrile neutropenia.
* Less severe neutropenia.
* Quicker hematological recovery.
* Challenges the “Maximal Tolerated Dose” Ideology: The study suggests that pushing for the highest possible dose of venetoclax isn’t always the best approach, as toxicity can lead to treatment discontinuation and worse outcomes.
Conclusion:
Reducing the dose or duration of venetoclax, when combined with HMA, can maintain efficacy while significantly improving patient tolerance and potentially extending survival in older/unfit AML patients. The authors advocate for a more nuanced approach to dosing,prioritizing treatment persistence over maximizing the initial dose.
Limitations:
* Small sample size.
* Short follow-up period.
* Further research is needed to confirm these findings.
References Cited:
* dinardo et al. (2020) – VIALE-A trial establishing the standard dose.
* Ucciero et al. (2023) – Meta-analysis of real-world data showing survival issues with standard dose.
* Gross et al. (2023) – Real-world data on azacitidine and venetoclax use.
* Stampfer et al. (2019) – Discussion of the “maximum tolerated dose” concept.
